Sequence and Structure Signatures of Cancer Mutation Hotspots in Protein Kinases

Protein kinases are the most common protein domains implicated in cancer, where somatically acquired mutations are known to be functionally linked to a variety of cancers. Resequencing studies of protein kinase coding regions have emphasized the importance of sequence and structure determinants of cancer-causing kinase mutations in understanding of the mutation-dependent activation process. We have developed an integrated bioinformatics resource, which consolidated and mapped all currently available information on genetic modifications in protein kinase genes with sequence, structure and functional data. The integration of diverse data types provided a convenient framework for kinome-wide study of sequence-based and structure-based signatures of cancer mutations. The database-driven analysis has revealed a differential enrichment of SNPs categories in functional regions of the kinase domain, demonstrating that a significant number of cancer mutations could fall at structurally equivalent positions (mutational hotspots) within the catalytic core. We have also found that structurally conserved mutational hotspots can be shared by multiple kinase genes and are often enriched by cancer driver mutations with high oncogenic activity. Structural modeling and energetic analysis of the mutational hotspots have suggested a common molecular mechanism of kinase activation by cancer mutations, and have allowed to reconcile the experimental data. According to a proposed mechanism, structural effect of kinase mutations with a high oncogenic potential may manifest in a significant destabilization of the autoinhibited kinase form, which is likely to drive tumorigenesis at some level. Structure-based functional annotation and prediction of cancer mutation effects in protein kinases can facilitate an understanding of the mutation-dependent activation process and inform experimental studies exploring molecular pathology of tumorigenesis.

[1]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[2]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[3]  Ben J. Powell,et al.  Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Thomas,et al.  Coding single-nucleotide polymorphisms associated with complex vs. Mendelian disease: evolutionary evidence for differences in molecular effects. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Skolnick,et al.  TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.

[6]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[7]  T. Hunter,et al.  The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  Frances M. G. Pearl,et al.  MoKCa database—mutations of kinases in cancer , 2008, Nucleic Acids Res..

[9]  Gennady M Verkhivker,et al.  Cancer driver mutations in protein kinase genes. , 2009, Cancer letters.

[10]  L. Schmidt,et al.  The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants , 2004, Oncogene.

[11]  L. Ashman,et al.  Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. , 2003, Leukemia research.

[12]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[13]  C. Brooks,et al.  Large-scale allosteric conformational transitions of adenylate kinase appear to involve a population-shift mechanism , 2007, Proceedings of the National Academy of Sciences.

[14]  Giulio Superti-Furga,et al.  Dynamic Coupling between the SH2 and SH3 Domains of c-Src and Hck Underlies Their Inactivation by C-Terminal Tyrosine Phosphorylation , 2001, Cell.

[15]  François Stricher,et al.  The FoldX web server: an online force field , 2005, Nucleic Acids Res..

[16]  R. Dror,et al.  A conserved protonation-dependent switch controls drug binding in the Abl kinase , 2009, Proceedings of the National Academy of Sciences.

[17]  T. Hunter,et al.  The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  L. Schmidt,et al.  Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto‐oncogene: Modeling studies , 2001, Proteins.

[19]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Eric S. Lander,et al.  Journey to the Center of Biology , 2000, Science.

[21]  G. Parmigiani,et al.  Design and analysis issues in genome-wide somatic mutation studies of cancer. , 2009, Genomics.

[22]  P. Stenson,et al.  Human Gene Mutation Database—A biomedical information and research resource , 2000, Human mutation.

[23]  S. Tsai,et al.  EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy , 2008, Oncogene.

[24]  Michael Gribskov,et al.  Protein kinase resource: An integrated environment for phosphorylation research , 2006, Proteins.

[25]  Andrew D. Yates,et al.  Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.

[26]  M. Olivier A haplotype map of the human genome , 2003, Nature.

[27]  Christian Auclair,et al.  Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. , 2005, Journal of medicinal chemistry.

[28]  Susan S. Taylor,et al.  RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. , 2006, Cancer research.

[29]  Jun S. Liu,et al.  Gibbs motif sampling: Detection of bacterial outer membrane protein repeats , 1995, Protein science : a publication of the Protein Society.

[30]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[31]  Yan Zhang,et al.  CanPredict: a computational tool for predicting cancer-associated missense mutations , 2007, Nucleic Acids Res..

[32]  Ming Tang,et al.  PROMALS3D web server for accurate multiple protein sequence and structure alignments , 2008, Nucleic Acids Res..

[33]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[34]  Lynn F. Ten Eyck,et al.  A helix scaffold for the assembly of active protein kinases , 2008, Proceedings of the National Academy of Sciences.

[35]  P. Comoglio,et al.  Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. , 2002, Cancer research.

[36]  J. Reilly,et al.  Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia , 2001, British journal of haematology.

[37]  Elif Ozkirimli,et al.  Src kinase activation: A switched electrostatic network , 2006, Protein science : a publication of the Protein Society.

[38]  Gennady Verkhivker,et al.  Hierarchical Modeling of Activation Mechanisms in the ABL and EGFR Kinase Domains: Thermodynamic and Mechanistic Catalysts of Kinase Activation by Cancer Mutations , 2009, PLoS Comput. Biol..

[39]  A. Cavalli,et al.  Protein conformational transitions: the closure mechanism of a kinase explored by atomistic simulations. , 2009, Journal of the American Chemical Society.

[40]  Alfonso Valencia,et al.  Extraction of human kinase mutations from literature, databases and genotyping studies , 2009, BMC Bioinformatics.

[41]  Stefan Fröhling,et al.  Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. , 2007, Cancer cell.

[42]  Matthew Meyerson,et al.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.

[43]  Svend Kjær,et al.  Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain* , 2006, Journal of Biological Chemistry.

[44]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[45]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[46]  Renate Griffith,et al.  Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. , 2004, Journal of molecular graphics & modelling.

[47]  M. Olivier A haplotype map of the human genome. , 2003, Nature.

[48]  M. Vihinen,et al.  BTKbase: the mutation database for X‐linked agammaglobulinemia , 2006, Human mutation.

[49]  Michel Schneider,et al.  UniProtKB/Swiss-Prot. , 2007, Methods in molecular biology.

[50]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[51]  M. Michael Gromiha,et al.  CUPSAT: prediction of protein stability upon point mutations , 2006, Nucleic Acids Res..

[52]  T. Sawyer Novel oncogenic protein kinase inhibitors for cancer therapy. , 2004, Current medicinal chemistry. Anti-cancer agents.

[53]  Benoît Roux,et al.  Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories , 2009, Proceedings of the National Academy of Sciences.

[54]  L. Mulligan,et al.  Molecular Implications of RET Mutations for Pheochromocytoma Risk in Multiple Endocrine Neoplasia 2 , 2006, Annals of the New York Academy of Sciences.

[55]  Laura Sepp-Lorenzino,et al.  Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling. , 2004, Journal of molecular graphics & modelling.

[56]  Susan S. Taylor,et al.  Congenital disease SNPs target lineage specific structural elements in protein kinases , 2008, Proceedings of the National Academy of Sciences.

[57]  A. Dobrovic,et al.  Sensitive detection of KIT D816V in patients with mastocytosis. , 2006, Clinical chemistry.

[58]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[59]  Jun S. Liu,et al.  Detecting subtle sequence signals: a Gibbs sampling strategy for multiple alignment. , 1993, Science.

[60]  H. Erickson,et al.  High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia , 2009, Leukemia.

[61]  Tony Fletcher,et al.  Sequence variant on 8q24 confers susceptibility to urinary bladder cancer , 2008, Nature Genetics.

[62]  Susan S. Taylor,et al.  Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism , 2006, Proceedings of the National Academy of Sciences.

[63]  G. Casari,et al.  Automatic extraction of mutations from Medline and cross-validation with OMIM. , 2004, Nucleic acids research.

[64]  S. Eckhardt,et al.  Tyrosine kinase inhibitors in cancer therapy. , 2008, Anti-cancer agents in medicinal chemistry.

[65]  P. Stenson,et al.  Human Gene Mutation Database (HGMD®): 2003 update , 2003, Human mutation.

[66]  T. Zhou,et al.  Crystal Structure of the T315I Mutant of Abl Kinase , 2007, Chemical biology & drug design.

[67]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[68]  P. Accornero,et al.  K252a inhibits the oncogenic properties of Met, the HGF receptor , 2002, Oncogene.

[69]  T. Hunter,et al.  The protein kinases of budding yeast: six score and more. , 1997, Trends in biochemical sciences.

[70]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[71]  Benoît Roux,et al.  Src Kinase Conformational Activation: Thermodynamics, Pathways, and Mechanisms , 2008, PLoS Comput. Biol..

[72]  Philip E. Bourne,et al.  The RCSB PDB information portal for structural genomics , 2005, Nucleic Acids Res..

[73]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[74]  F. Lozupone,et al.  Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.

[75]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[76]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[77]  Fotini Tzortzatou-Stathopoulou,et al.  Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation , 2009, Proteins.

[78]  I. Weinstein Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[79]  Ming-Li Xiang,et al.  Detailed conformational dynamics of juxtamembrane region and activation loop in c‐Kit kinase activation process , 2008, Proteins.

[80]  G. Cheetham Novel protein kinases and molecular mechanisms of autoinhibition. , 2004, Current opinion in structural biology.

[81]  B. Roux,et al.  Anatomy of a structural pathway for activation of the catalytic domain of Src kinase Hck , 2007, Proteins.

[82]  T. Hunter,et al.  Evolution of protein kinase signaling from yeast to man. , 2002, Trends in biochemical sciences.

[83]  Francis S Collins,et al.  Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. , 2007, Scientific American.

[84]  C. Orengo,et al.  Cancer‐associated mutations are preferentially distributed in protein kinase functional sites , 2009, Proteins.

[85]  T. Hunter,et al.  Signaling—2000 and Beyond , 2000, Cell.

[86]  Adrian A Canutescu,et al.  Access the most recent version at doi: 10.1110/ps.03154503 References , 2003 .

[87]  Dietmar Schomburg,et al.  Computational modeling of protein mutant stability: analysis and optimization of statistical potentials and structural features reveal insights into prediction model development , 2007, BMC Structural Biology.

[88]  Francis S. Collins,et al.  Mapping the cancer genome , 2007 .

[89]  Gennady Verkhivker,et al.  Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. , 2009, Biophysical journal.

[90]  Alexander D. MacKerell,et al.  Development and current status of the CHARMM force field for nucleic acids , 2000, Biopolymers.

[91]  D. Williams,et al.  Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. , 2004, Current medicinal chemistry.

[92]  Maria Jesus Martin,et al.  The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..

[93]  A. Sali,et al.  Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.

[94]  Andrew D. Yates,et al.  A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer , 2005, Nature Genetics.

[95]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[96]  Balazs Halmos,et al.  Structure and clinical relevance of the epidermal growth factor receptor in human cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Benoît Roux,et al.  Flexibility and charge asymmetry in the activation loop of Src tyrosine kinases , 2009, Proteins.

[98]  Joaquín Dopazo,et al.  PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level , 2004, Nucleic Acids Res..

[99]  E S Lander,et al.  Genomics: journey to the center of biology. , 2000, Science.

[100]  A. Bardelli,et al.  Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Gerard Manning,et al.  Structural and Functional Diversity of the Microbial Kinome , 2007, PLoS biology.

[102]  M. Vihinen,et al.  KinMutBase: A registry of disease‐causing mutations in protein kinase domains , 2005, Human mutation.

[103]  Rakesh Nagarajan,et al.  Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. , 2008, Blood.

[104]  B. Peters,et al.  Distinguishing cancer-associated missense mutations from common polymorphisms. , 2007, Cancer research.

[105]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[106]  Philip E. Bourne,et al.  Structural Evolution of the Protein Kinase–Like Superfamily , 2005, PLoS Comput. Biol..

[107]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[108]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[109]  Sreenath V. Sharma,et al.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.

[110]  D. Maritano,et al.  Two mutations affecting conserved residues in the Met receptor operate via different mechanisms , 2000, Oncogene.

[111]  Carol Beth Post,et al.  An electrostatic network and long‐range regulation of Src kinases , 2008, Protein science : a publication of the Protein Society.

[112]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[113]  Zhaohui S. Qin,et al.  A second generation human haplotype map of over 3.1 million SNPs , 2007, Nature.

[114]  L. Serrano,et al.  Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.

[115]  S. Fröhling,et al.  High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. , 2007, Blood.

[116]  P. Stenson,et al.  Human Gene Mutation Database (HGMD , 2003 .

[117]  John Kuriyan,et al.  Protein-protein interactions in the allosteric regulation of protein kinases. , 2006, Current opinion in structural biology.

[118]  C. Sawyers Opportunities and challenges in the development of kinase inhibitor therapy for cancer. , 2003, Genes & development.

[119]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[120]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[121]  Susan S. Taylor,et al.  Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.

[122]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[123]  L. Mulligan,et al.  Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. , 2006, Cancer research.

[124]  Jun S. Liu,et al.  Gapped alignment of protein sequence motifs through Monte Carlo optimization of a hidden Markov model , 2004, BMC Bioinformatics.

[125]  Nathaniel J. Traaseth,et al.  Allosteric cooperativity in protein kinase A , 2008, Proceedings of the National Academy of Sciences.

[126]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[127]  D. Altshuler,et al.  Completing the map of human genetic variation , 2007, Nature.

[128]  L. Schmidt,et al.  Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src , 2000, Oncogene.

[129]  P. Comoglio,et al.  Mutations in the met Oncogene Unveil a “Dual Switch” Mechanism Controlling Tyrosine Kinase Activity* , 2003, Journal of Biological Chemistry.

[130]  L. Schmidt,et al.  Activating mutations for the met tyrosine kinase receptor in human cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[131]  S. Knapp,et al.  Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[132]  L. Mulligan,et al.  RET Signaling in Endocrine Tumors: Delving Deeper into Molecular Mechanisms , 2007, Endocrine pathology.

[133]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[134]  M. Campbell,et al.  PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.

[135]  F. Lu,et al.  The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.

[136]  K. Sirotkin,et al.  dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. , 1999, Genome research.

[137]  N. Schork,et al.  Prediction of cancer driver mutations in protein kinases. , 2008, Cancer research.

[138]  Nicholas J. Schork,et al.  Accurate prediction of deleterious protein kinase polymorphisms , 2007, Bioinform..

[139]  B. Druker,et al.  Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.

[140]  A. F. Neuwald,et al.  Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? , 2005, Journal of molecular biology.

[141]  Antonella Isacchi,et al.  Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. , 2007, Cancer research.

[142]  Mauno Vihinen,et al.  KinMutBase, a database of human disease-causing protein kinase mutations , 1999, Nucleic Acids Res..

[143]  D. Cooper,et al.  Protein Kinases as Therapeutic Targets , 2000, Pharmaceutical Research.